Michael W. Dunne

This profile gathers the share dealings of Michael W. Dunne in Iterum Therapeutics plc, where the filings describe the role as board member. We count 24 filings; the first trade dates from 30 May 2018 and the latest from 18 November 2025.

The open-market record is one-sided, with 11 purchases worth €119k and not one sale. The totals exclude 1 filing filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 share grant and 9 option exercises. In 2025 alone, the filings show 2 purchases and no sales.

In size, the median ticket on the buying side is €5,593. Clusters matter here: 5 out of 10 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

On 20 November 2025 came the latest disclosure, an open-market purchase for €1,891 in Iterum Therapeutics plc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.